Literature DB >> 27868036

The state of the art in prediction of breast cancer relapse using cell-free circulating tumor DNA liquid biopsies.

Niklas Loman1, Lao H Saal2.   

Abstract

Entities:  

Year:  2016        PMID： 27868036      PMCID： PMC5104597          DOI： 10.21037/atm.2016.10.58

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  17 in total

1.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Authors:  Isaac Garcia-Murillas; Gaia Schiavon; Britta Weigelt; Charlotte Ng; Sarah Hrebien; Rosalind J Cutts; Maggie Cheang; Peter Osin; Ashutosh Nerurkar; Iwanka Kozarewa; Javier Armisen Garrido; Mitch Dowsett; Jorge S Reis-Filho; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

2.  PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.

Authors:  Chiya Oshiro; Naofumi Kagara; Yasuto Naoi; Masafumi Shimoda; Atsushi Shimomura; Naomi Maruyama; Kenzo Shimazu; Seung Jin Kim; Shinzaburo Noguchi
Journal:  Breast Cancer Res Treat       Date:  2015-03-04       Impact factor: 4.872

3.  Detection of circulating tumor DNA in early- and late-stage human malignancies.

Authors:  Chetan Bettegowda; Mark Sausen; Rebecca J Leary; Isaac Kinde; Yuxuan Wang; Nishant Agrawal; Bjarne R Bartlett; Hao Wang; Brandon Luber; Rhoda M Alani; Emmanuel S Antonarakis; Nilofer S Azad; Alberto Bardelli; Henry Brem; John L Cameron; Clarence C Lee; Leslie A Fecher; Gary L Gallia; Peter Gibbs; Dung Le; Robert L Giuntoli; Michael Goggins; Michael D Hogarty; Matthias Holdhoff; Seung-Mo Hong; Yuchen Jiao; Hartmut H Juhl; Jenny J Kim; Giulia Siravegna; Daniel A Laheru; Calogero Lauricella; Michael Lim; Evan J Lipson; Suely Kazue Nagahashi Marie; George J Netto; Kelly S Oliner; Alessandro Olivi; Louise Olsson; Gregory J Riggins; Andrea Sartore-Bianchi; Kerstin Schmidt; le-Ming Shih; Sueli Mieko Oba-Shinjo; Salvatore Siena; Dan Theodorescu; Jeanne Tie; Timothy T Harkins; Silvio Veronese; Tian-Li Wang; Jon D Weingart; Christopher L Wolfgang; Laura D Wood; Dongmei Xing; Ralph H Hruban; Jian Wu; Peter J Allen; C Max Schmidt; Michael A Choti; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Nickolas Papadopoulos; Luis A Diaz
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

4.  Circulating mutant DNA to assess tumor dynamics.

Authors:  Frank Diehl; Kerstin Schmidt; Michael A Choti; Katharine Romans; Steven Goodman; Meng Li; Katherine Thornton; Nishant Agrawal; Lori Sokoll; Steve A Szabo; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Nat Med       Date:  2007-07-31       Impact factor: 53.440

5.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Authors:  L De Mattos-Arruda; B Weigelt; J Cortes; H H Won; C K Y Ng; P Nuciforo; F-C Bidard; C Aura; C Saura; V Peg; S Piscuoglio; M Oliveira; Y Smolders; P Patel; L Norton; J Tabernero; M F Berger; J Seoane; J S Reis-Filho
Journal:  Ann Oncol       Date:  2014-07-09       Impact factor: 32.976

6.  Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Authors:  Gaia Schiavon; Sarah Hrebien; Isaac Garcia-Murillas; Rosalind J Cutts; Alex Pearson; Noelia Tarazona; Kerry Fenwick; Iwanka Kozarewa; Elena Lopez-Knowles; Ricardo Ribas; Ashutosh Nerurkar; Peter Osin; Sarat Chandarlapaty; Lesley-Ann Martin; Mitch Dowsett; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-11-11       Impact factor: 17.956

7.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Authors:  Peilu Wang; Amir Bahreini; Rekha Gyanchandani; Peter C Lucas; Ryan J Hartmaier; Rebecca J Watters; Amruth R Jonnalagadda; Humberto E Trejo Bittar; Aaron Berg; Ronald L Hamilton; Brenda F Kurland; Kurt R Weiss; Aju Mathew; Jose Pablo Leone; Nancy E Davidson; Marina N Nikiforova; Adam M Brufsky; Tadeu F Ambros; Andrew M Stern; Shannon L Puhalla; Adrian V Lee; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

8.  Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.

Authors:  Sarat Chandarlapaty; David Chen; Wei He; Patricia Sung; Aliaksandra Samoila; Daoqi You; Trusha Bhatt; Parul Patel; Maurizio Voi; Michael Gnant; Gabriel Hortobagyi; José Baselga; Mary Ellen Moynahan
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

9.  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.

Authors:  F Cardoso; A Costa; L Norton; E Senkus; M Aapro; F André; C H Barrios; J Bergh; L Biganzoli; K L Blackwell; M J Cardoso; T Cufer; N El Saghir; L Fallowfield; D Fenech; P Francis; K Gelmon; S H Giordano; J Gligorov; A Goldhirsch; N Harbeck; N Houssami; C Hudis; B Kaufman; I Krop; S Kyriakides; U N Lin; M Mayer; S D Merjaver; E B Nordström; O Pagani; A Partridge; F Penault-Llorca; M J Piccart; H Rugo; G Sledge; C Thomssen; L Van't Veer; D Vorobiof; C Vrieling; N West; B Xu; E Winer
Journal:  Ann Oncol       Date:  2014-09-18       Impact factor: 32.976

10.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.

Authors:  Muhammed Murtaza; Sarah-Jane Dawson; Katherine Pogrebniak; Oscar M Rueda; Elena Provenzano; John Grant; Suet-Feung Chin; Dana W Y Tsui; Francesco Marass; Davina Gale; H Raza Ali; Pankti Shah; Tania Contente-Cuomo; Hossein Farahani; Karey Shumansky; Zoya Kingsbury; Sean Humphray; David Bentley; Sohrab P Shah; Matthew Wallis; Nitzan Rosenfeld; Carlos Caldas
Journal:  Nat Commun       Date:  2015-11-04       Impact factor: 14.919
View more
  2 in total

1.  Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment.

Authors:  Lao H Saal; Lisa Rydén; Daniel Förnvik; Kristina E Aaltonen; Yilun Chen; Anthony M George; Christian Brueffer; Robert Rigo; Niklas Loman
Journal:  Breast Cancer Res Treat       Date:  2019-06-24       Impact factor: 4.872

2.  Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative.

Authors:  L Rydén; N Loman; C Larsson; C Hegardt; J Vallon-Christersson; M Malmberg; H Lindman; A Ehinger; L H Saal; Å Borg
Journal:  Br J Surg       Date:  2018-01       Impact factor: 6.939
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.